CHRU NANCY Brabois, nuclear medicine department
Vandœuvre-lès-Nancy, 54511, France
NCT Number: NCT06828705
Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).
Looking for future studies?
Notify Me18 year–99 year
All sexes
Observational
Vandœuvre-lès-Nancy, 54511, France
Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).
There are several types of cameras allowing its performance:
The objectives are therefore to:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Semi-quantitative analysis on Datscan imaging scintigraphy
Time frame: One day
Fixation ratio of central gray nuclei of the brain namely, the global striatum, caudate nuclei, putamens
Time frame: One day
Identical to the primary evaluation criterion compared to those of the Lyon database.
Central Hospital, Nancy, France
Other
Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride (CZT) Camera (VERITON-CT)
Acronym: DaTBase
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05318976
Alzheimer Disease, Brain Diseases
Darlinghurst, New South Wales, Australia
View Trial DetailsNCT06122662
Atypical Parkinsonism, Basal Ganglia Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT06579209
Cognitive Change, Inflammation
Kingston, Rhode Island, United States
View Trial DetailsNCT05095870
Ataxia, Brain Diseases
Nîmes, France
View Trial Details